Role of PELP1/MNAR signaling in ovarian tumorigenesis
- PMID: 18559538
- DOI: 10.1158/0008-5472.CAN-07-5698
Role of PELP1/MNAR signaling in ovarian tumorigenesis
Abstract
Emerging evidence suggests that nuclear receptor (NR) coregulators have potential to act as master genes and their deregulation can promote oncogenesis. Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1/MNAR) is a novel NR coregulator. Its expression is deregulated in hormone-driven cancers. However, the role of PELP1/MNAR in ovarian cancer progression remains unknown. Analysis of serial analysis of gene expression data suggested deregulation of PELP1/MNAR expression in ovarian tumors. Western analysis of PELP1/MNAR in normal and serous ovarian tumor tissues showed 3- to 4-fold higher PELP1/MNAR expression in serous tumors compared with normal ovarian tissues. To examine the significance of PELP1/MNAR in ovarian cancer progression, we have generated model cells that overexpress PELP1/MNAR and ovarian cancer cells in which PELP1/MNAR expression is down-regulated by stable expression of PELP1/MNAR-specific shRNA. Down-regulation of PELP1/MNAR in cancerous ovarian model cells (OVCAR3) resulted in reduced proliferation, affected the magnitude of c-Src and protein kinase B (AKT) signaling, and reduced tumorigenic potential of ovarian cancer cells in a nude mouse model. PELP1/MNAR overexpression in nontumorigenic immortalized surface epithelial cells (IOSE cells) promoted constitutive activation of c-Src and AKT signaling pathways and promoted anchorage-independent growth. Immunohistochemical studies using human ovarian cancer tissue arrays (n = 123) showed that PELP1/MNAR is 2- to 3-fold overexpressed in 60% of ovarian tumors, and PELP1/MNAR deregulation occurs in all different types of ovarian cancer. Collectively, these results suggest that PELP1/MNAR signaling plays a role in ovarian cancer cell proliferation and survival, and that its expression is deregulated in ovarian carcinomas.
Similar articles
-
Emerging significance of ER-coregulator PELP1/MNAR in cancer.Histol Histopathol. 2007 Jan;22(1):91-6. doi: 10.14670/HH-22.91. Histol Histopathol. 2007. PMID: 17128415 Free PMC article. Review.
-
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.Mol Endocrinol. 2008 Mar;22(3):649-64. doi: 10.1210/me.2007-0350. Epub 2007 Dec 13. Mol Endocrinol. 2008. PMID: 18079323 Free PMC article.
-
Regulation of aromatase induction by nuclear receptor coregulator PELP1.J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):211-8. doi: 10.1016/j.jsbmb.2009.09.009. Epub 2009 Sep 30. J Steroid Biochem Mol Biol. 2010. PMID: 19800002 Free PMC article.
-
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.Cancer Res. 2007 Jun 1;67(11):5505-12. doi: 10.1158/0008-5472.CAN-06-3647. Cancer Res. 2007. PMID: 17545633 Free PMC article.
-
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR.Nucl Recept Signal. 2007 May 17;5:e004. doi: 10.1621/nrs.05004. Nucl Recept Signal. 2007. PMID: 17525794 Free PMC article. Review.
Cited by
-
PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.Mol Carcinog. 2020 Mar;59(3):281-292. doi: 10.1002/mc.23152. Epub 2019 Dec 24. Mol Carcinog. 2020. PMID: 31872914 Free PMC article.
-
PELP1: a review of PELP1 interactions, signaling, and biology.Mol Cell Endocrinol. 2014 Jan 25;382(1):642-651. doi: 10.1016/j.mce.2013.07.031. Epub 2013 Aug 8. Mol Cell Endocrinol. 2014. PMID: 23933151 Free PMC article. Review.
-
Significance of ER-Src axis in hormonal therapy resistance.Breast Cancer Res Treat. 2011 Nov;130(2):377-85. doi: 10.1007/s10549-010-1312-2. Epub 2010 Dec 24. Breast Cancer Res Treat. 2011. PMID: 21184269 Free PMC article.
-
Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.Cancers (Basel). 2024 Jan 24;16(3):500. doi: 10.3390/cancers16030500. Cancers (Basel). 2024. PMID: 38339252 Free PMC article.
-
Src family kinases and paclitaxel sensitivity.Cancer Biol Ther. 2011 Aug 15;12(4):260-9. doi: 10.4161/cbt.12.4.16430. Epub 2011 Aug 15. Cancer Biol Ther. 2011. PMID: 21646863 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous